Growth Failure as a Prognostic Indicator of Mortality in Pediatric HIV Infection

Rahel Berhane, MD*; Danstan Bagenda, MSc†; Lawrence Marum, MD, MPH§; Esther Aceng, MB ChB, MPH¶; Christopher Nduigwa, MB ChB, MMed¶; Ronald J Bosch, PhD∥; and Karen Olness, MD§

ABSTRACT. Objective. To study the effect of perinatally acquired human immunodeficiency virus (HIV) on somatic growth and examine the relationship of nutritional status to mortality in HIV-infected infants.

Method. Pregnant women attending the antenatal clinic at Mulago hospital in Kampala, Uganda, were enrolled. All live-born babies born to HIV-1 seropositive (HIV+) women, and to every fourth age-matched HIV-1 seronegative (HIV−) woman, were followed for 25 months.

Results. The mean weight-for-age and length-for-age curves of HIV+ children were significantly lower than those of HIV− controls and seroconverters. Forty-five (54%) of the 84 HIV+ infants died before their second birthday, as compared with a 1.6% and 5.6% mortality in HIV− and seroconverters. HIV+ infants with an average weight-for-age Z-score below −1.5 in the first year of life have a nearly fivefold risk of dying before 25 months of age compared with noninfected controls.

Conclusion. Perinatally acquired HIV infection is associated with early and progressive growth failure. The severity of growth failure is associated with an increased risk of mortality. The effect of early, aggressive nutritional intervention in delaying HIV progression and mortality should be evaluated by controlled intervention studies.

PATIENTS AND METHODS

Study Patients

Pregnant women attending the antenatal clinic at Mulago hospital in Kampala, Uganda from 1990–1992 were enrolled in a study of HIV-1 infection in pregnancy sponsored by the World Health Organization in collaboration with the Department of Obstetrics and Gynaecology at Makerere University Medical School in Kampala. Women were eligible for the study if they were less than 28 weeks gestation, lived within 15 km of the hospital, were willing to be tested for HIV-1 and were willing to deliver at Mulago Hospital. All live-born infants born to HIV+ mothers and to every fourth age-matched HIV− mother were enrolled in the pediatric studies. The overall HIV-1 seroprevalence rate of pregnant women was 28%. Five hundred twenty term infants were enrolled in the study. The children did not receive zidovudine or any other antiretroviral agent at any point during follow-up.

HIV Status

Blood was obtained from study infants at birth, 6 weeks, 6 months, 12 months and >15 months. HIV-1 status was determined by HIV-1 enzyme immunoassay (EIA) at >15 months in surviving infants with confirmatory Western blots of all seropositives. Western blots were considered positive if they contained any two of the following HIV-1 specific bands: gp160/120, gp41 or p24. Patients were classified as HIV Infected (HIV+) if both the mother and infant were positive by both EIA and Western blot techniques. HIV-1 DNA polymerase chain reaction (PCR) and immune complex dissociation (ICD) p24 antigen testing were performed on specimens from children who were lost or had died before 15 months of age. Of the 84 children who were found to be HIV+, 49 had a positive serology based on EIA and Western blot at or beyond 15 months of age. Of the remaining 35, 29 were positive by more than one early diagnostic test (p24 and PCR). Three were based on PCR alone and three were based on ICD p24 antigen testing alone. ICD p24 was never used as the sole criterion in infants less than 1 month of age. Infants who were born to HIV+ mothers but were seronegative were classified as seroconverters.
Infants who were born to HIV-negative (HIV−) mothers and were themselves negative were classified as HIV−.

**Anthropometric Measurements**

Birth weight was obtained from delivery room records and length measured by pediatrician at the time of first visit. Subsequent anthropometric measurements were performed by two experienced nurses trained in standard anthropometric techniques. Measurements were scheduled to be taken every month up to 3 months of age and every 3 months thereafter until 2 years of age. Subjects were weighed unclothed on a hanging Salter scale. Length was measured in a recumbent position using a length board stadiometer. All measurements from birth to 25 months of age were included in the analysis.

**Statistical Analysis**

Data were entered using the EPI-INFO program (Centers for Disease Control and Prevention, Atlanta, GA), which was also used to compute weight-for-age Z-scores (WAZ). The weight-for-age Z-score represents the number of standard deviations above/below the median weight for a reference population at that age.7,8 Analysis was performed using SAS.9 The generalized estimating equation (GEE) approach was used to model longitudinal weight and length data. This regression method can analyze data sets with a variable number of measurements per individual and takes into account the correlation between repeated measurements on the same child.10,11 After an exploratory phase, the regression model (see Fig 1 and Fig 2) was chosen to be a 6-parameter cubic spline with knots at 6 and 12 months.12 In the GEE analysis, robust variance estimates and the exchangeable working correlation matrix were used. Fisher’s exact test was used to test for differences in mortality and for the association between nutritional status and mortality. Analysis of variance was used to compare birth weights and lengths.

**RESULTS**

Five hundred twenty infants were followed prospectively from birth. Eighty-four (16.2%) of the children were HIV+. One hundred twenty-four (23.8%) of the children were negative. Two hundred fifty-one (48.3%) were seroverters.

Sixty-one children (11.7%) were unclassified and were excluded from the analysis. The unclassified group consisted of 35 infants who were born to HIV+ mothers but had equivocal results, 11 who were HIV− born to mothers who had equivocal HIV results, 7 with equivocal HIV results born to mothers who are negative, and 8 infants born to mothers who did not have Western blot testing to confirm HIV positivity.

Of the 459 patients with known HIV status, 51.9% were male and 48.1% were female. A total of 3820 weight measurements and 3811 length measurements were available for ages 0 to 25 months (mean of 8.3; range 1–11 measurements/child). Apgar scores, Dubowitz scores, gender, socioeconomic status, duration of breastfeeding, and ethnic background were not different between HIV+ infants, seroverters and HIV− controls.

The distribution of birth weight and length in the three groups is shown in Table 1. Mean weight-for-age and length-for-age curves for each of the three groups are as shown in Figs 1 and 2. The three weight-for-age curves are significantly different (P < .0001). The weight-for-age curve for HIV+ children differs significantly from that of HIV− controls and of seroverters (P = .0012 and P < .0001, respectively). At 6 months of age, HIV+ children had a significantly lower mean weight than both HIV− and seroverters (P = .004 and P = .027). Similarly, (see Fig 2), differences are noted in the length-for-age curves between HIV+, HIV− and seroverters (P < .0001). Growth differences between the three groups

**TABLE 1.** Birth Weight and Length (mean ± SD), in HIV-positive, HIV-negative, and Seroeverter Ugandan Infants

<table>
<thead>
<tr>
<th></th>
<th>Birth Weight (kg)</th>
<th>Birth Length (cm)</th>
</tr>
</thead>
<tbody>
<tr>
<td>HIV-positive</td>
<td>2.97 ± 0.53</td>
<td>49.97 ± 3.14</td>
</tr>
<tr>
<td>HIV-negative</td>
<td>3.03 ± 0.49</td>
<td>49.95 ± 2.50</td>
</tr>
<tr>
<td>Seroverters</td>
<td>2.87 ± 0.44</td>
<td>49.34 ± 2.37</td>
</tr>
</tbody>
</table>

Seroverters had a lower birth weight and length; P = .047, .051, respectively.

**TABLE 2.** Mortality Distribution of Infants Born to HIV-Infected Women by Infant’s HIV Status at Mulago Hospital, Uganda (1990–1992)

<table>
<thead>
<tr>
<th>Age at Death</th>
<th>HIV-positive</th>
<th>HIV-negative</th>
<th>Seroverters</th>
</tr>
</thead>
<tbody>
<tr>
<td>0–&lt;6 months</td>
<td>13 (15.5%)</td>
<td>...</td>
<td>...</td>
</tr>
<tr>
<td>6–&lt;12 months</td>
<td>12 (14.3%)</td>
<td>...</td>
<td>5 (2.0%)</td>
</tr>
<tr>
<td>12–&lt;18 months</td>
<td>9 (10.7%)</td>
<td>2 (1.6%)</td>
<td>7 (2.8%)</td>
</tr>
<tr>
<td>18–&lt;25 months</td>
<td>11 (13.1%)</td>
<td>...</td>
<td>2 (0.8%)</td>
</tr>
<tr>
<td>≥25 months (alive by 25 months)</td>
<td>39 (46.4%)</td>
<td>122 (98.4%)</td>
<td>237 (94.4%)</td>
</tr>
</tbody>
</table>

Fig 1. Mean weight-for-age in HIV+, HIV−, and seroeverter infants.

Fig 2. Mean length-for-age in HIV+, HIV−, and seroeverter infants.
persists even when children with early mortality (death before 25 months of age) are excluded (data not shown).

Sixty-one patients died during the period of observation. Table 2 shows the distribution of mortality by group and age at death. Forty-five of 84 HIV+ infants (54%) died before their second birthday, a significantly higher proportion than of HIV- controls and seroeverters (both P < .0001). Among the HIV+ infants, those with an average weight-for-age Z-score below −1.5 over the first year of life have a nearly fivefold odds of dying before 25 months of age compared with those with WAZ more than −1.5 (Table 3). Low weight-for-age Z-scores in the first 6 months of life were also associated with increased mortality rate by 25 months of age.

**DISCUSSION**

Our analysis demonstrates that perinatally acquired HIV infection is associated with early and progressive decrements in weight and length. The differences in weight and height between the HIV+ children and controls persisted even when patients who died before 25 months of age were removed from analysis. This finding is consistent with findings from other studies and suggests that this relationship is not totally caused by a subpopulation of very ill children.

Although almost half of the HIV+ children died before 25 months of age, as compared with only 5.6 and 1.6% of seroeverters and negatives respectively. This mortality rate is consistent with reports from Haiti and Zaire, but is much higher than mortality rates reported from Europe and North America, where median survival of about 4 years of age are reported. The poor outcome in the HIV+ infants cannot all be attributed to poverty and underdevelopment, because the control groups shared the same socioeconomic environment.

Our data show a striking inverse association between early nutritional status and mortality risk. The association between nutritional status and mortality is consistent with findings in a Rwandan cohort, where an inverse association between nutritional status at 12 months of age and mortality by the second birthday was demonstrated. Similar findings were also reported in a US study which found weight below the third percentile to be a relatively specific (93%), although not sensitive (31%) predictor of mortality.

The strong association between poor growth and mortality suggests two possible mechanisms. First, poor nutritional parameters may represent the general debilitation of infants with frequent opportunistic infections who eventually succumb and die. The association of infection-induced cachexia to mortality has been well documented in adult acquired immune deficiency syndrome (AIDS) patients and is probably induced by the effect of recurrent infections on food intake, absorption and energy expenditure.

An alternative possibility is that poor nutritional status accelerates the progression from asymptomatic HIV infection to AIDS. This possibility cannot be definitively confirmed from our data. Large population studies that compared survival in perinatally acquired HIV with transfusion-acquired disease have shown that differences in HIV mortality between the two groups were due to differences in median symptom-free survival alone. Survival after development of symptoms was similar in the two groups. The possibility that poor nutrition may shorten the symptom-free interval is also suggested by reports on HIV-infected hemophiliacs, in which a decrease in growth velocity identifies children in whom symptoms will develop. The determinants of this nutrition-immunity interaction remain to be delineated.

In summary, perinatally acquired HIV infection is associated with early and progressive growth failure. The severity of growth failure is associated with an increased risk of early mortality. These data suggest that poor nutritional status may play a major role in the progression of asymptomatic HIV infection to AIDS. The effect of early aggressive nutritional intervention in delaying HIV progression and mortality should be evaluated by controlled intervention studies.

**ACKNOWLEDGMENTS**

This work was supported by National Institutes of Health grant NS28631.

We express our appreciation to the Catholic Agency for Overseas Development for provision of a vehicle; Rotary International for provision of necessities to mothers and children; to the nurses, health visitors; and Ward 11 staff of the Makerere University/Case Western Reserve University research collaboration; and to the Fogarty Institute for training activities. We would also like to thank Dr Laura Guay for reviewing the manuscript.

**REFERENCES**

Growth Failure as a Prognostic Indicator of Mortality in Pediatric HIV Infection
Rahel Berhane, Danstan Bagenda, Lawrence Marum, Esther Aceng, Christopher Ndugwa, Ronald J Bosch and Karen Olness

_Pediatrics_ 1997;100;e7
DOI: 10.1542/peds.100.1.e7

Updated Information & Services
including high resolution figures, can be found at: /content/100/1/e7.full.html

References
This article cites 20 articles, 5 of which can be accessed free at: /content/100/1/e7.full.html#ref-list-1

Citations
This article has been cited by 8 HighWire-hosted articles: /content/100/1/e7.full.html#related-urls

Subspecialty Collections
This article, along with others on similar topics, appears in the following collection(s):
_Infectious Disease_ /cgi/collection/infectious_diseases_sub

Permissions & Licensing
Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at: /site/misc/Permissions.xhtml

Reprints
Information about ordering reprints can be found online: /site/misc/reprints.xhtml

PEDIATRICS is the official journal of the American Academy of Pediatrics. A monthly publication, it has been published continuously since 1948. PEDIATRICS is owned, published, and trademarked by the American Academy of Pediatrics, 141 Northwest Point Boulevard, Elk Grove Village, Illinois, 60007. Copyright © 1997 by the American Academy of Pediatrics. All rights reserved. Print ISSN: 0031-4005. Online ISSN: 1098-4275.
Growth Failure as a Prognostic Indicator of Mortality in Pediatric HIV Infection
Rahel Berhane, Danstan Bagenda, Lawrence Marum, Esther Aceng, Christopher Ndugwa, Ronald J Bosch and Karen Olness

Pediatrics 1997;100:e7
DOI: 10.1542/peds.100.1.e7

The online version of this article, along with updated information and services, is located on the World Wide Web at:
/content/100/1/e7.full.html